Compare Invesco WilderHill Clean Energy ETF (PBW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs Recursion Pharmaceuticals Inc — how do they compare? Invesco WilderHill Clean Energy ETF trades at $33.85, while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PBW | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $6.79 |
52-Week Low | $22.23 | $2.84 |
Market Cap | — | $1.63B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW trades at $33.21, down 0.54% today, amid a bearish technical signal with moving averages indicating strong selling pressure. The ETF shows oversold conditions on short-term RSI readings but faces headwinds from sector volatility. Recent news highlights clean energy's potential tailwinds from energy security concerns and data center demand, though the fund remains sensitive to interest rate movements and semiconductor market swings.
The outlook for PBW is cautious; while clean energy thematic demand provides long-term opportunity, near-term risks include interest rate sensitivity and tech sector correlation. Investors face volatility from macroeconomic factors and sector-specific pressures, requiring careful risk assessment amid mixed technical and fundamental signals.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
